StockData
Q32 Bio Inc. logo

Q32 Bio Inc. (QTTB) stock

QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$8.53−0.10 (-1.16%)

Close on Nov 18, 2026Market cap $253.93MP/E –Yield –

Q32 Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Q32 Bio's operating income for the twelve months ending Jun 30, 2026 was $21.46M. For fiscal 2025 it was $16.90M. The highest annual figure on record is $16.90M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.90M–
FY2024Dec 31, 2024-$66.10M–
FY2023Dec 31, 2023-$48.26M–
FY2022Dec 31, 2022-$133.28M–
FY2021Dec 31, 2021-$95.95M–
FY2020Dec 31, 2020-$130.26M–
FY2019Dec 31, 2019-$109.94M–
FY2018Dec 31, 2018-$59.93M–
FY2017Dec 31, 2017-$29.66M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.12M–
Q1 FY2026Mar 31, 2026-$7.72M–
Q4 FY2025Dec 31, 2025$45.88M–
Q3 FY2025Sep 30, 2025-$7.58M–
Q2 FY2025Jun 30, 2025-$9.17M–
Q1 FY2025Mar 31, 2025-$12.23M–
Q4 FY2024Dec 31, 2024-$14.53M–
Q3 FY2024Sep 30, 2024-$18.81M–
Q2 FY2024Jun 30, 2024-$17.92M–
Q1 FY2024Mar 31, 2024-$14.84M–
Q4 FY2023Dec 31, 2023-$25.81M–
Q3 FY2023Sep 30, 2023-$7.80M–
Q2 FY2023Jun 30, 2023-$7.28M–
Q1 FY2023Mar 31, 2023-$7.37M–
Q4 FY2022Dec 31, 2022-$34.49M–
Q3 FY2022Sep 30, 2022-$32.86M–
Q2 FY2022Jun 30, 2022-$28.31M–
Q1 FY2022Mar 31, 2022-$37.62M–
Q4 FY2021Dec 31, 2021-$33.63M–
Q3 FY2021Sep 30, 2021-$30.66M–
Q2 FY2021Jun 30, 2021-$30.55M–
Q1 FY2021Mar 31, 2021-$1.11M–
Q4 FY2020Dec 31, 2020-$29.80M–
Q3 FY2020Sep 30, 2020-$28.27M–
Q2 FY2020Jun 30, 2020-$35.70M–
Q1 FY2020Mar 31, 2020-$36.49M–
Q4 FY2019Dec 31, 2019-$25.56M–
Q3 FY2019Sep 30, 2019-$31.29M–
Q2 FY2019Jun 30, 2019-$27.97M–
Q1 FY2019Mar 31, 2019-$25.12M–
Q4 FY2018Dec 31, 2018-$20.17M–
Q3 FY2018Sep 30, 2018-$15.64M–
Q2 FY2018Jun 30, 2018-$13.42M–
Q1 FY2018Mar 31, 2018-$10.70M–
Q4 FY2017Dec 31, 2017-$12.26M–
Q3 FY2017Sep 30, 2017-$6.66M–
Q2 FY2017Jun 30, 2017-$6.04M–
Q1 FY2017Mar 31, 2017-$4.69M–

More Q32 Bio figures

See a number that looks wrong?